CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT
A Phase II Prospective Randomized Trial of Donor T-memory Cells (CD45RA Depleted) Infusion for Prevention of Infections After Allogeneic TcRαβ/CD19-depleted Hematopoietic Stem Cell Transplantation
Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology
A PHASE2/PHASE3 clinical study on Graft-versus-Host Disease and GvHD, this trial is completed. The trial is conducted by Federal Research Institute of Pediatric Hematology, Oncology and Immunology and has accumulated 12 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Apr 2023 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
Status: Unknown Status → Completed
-
Mar 2022 — Apr 2023 [monthly]
Unknown Status PHASE2_PHASE3
Status: Active Not Recruiting → Unknown Status
▶ Show 7 earlier versions
-
Jan 2021 — Mar 2022 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Mar 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2019 — Mar 2020 [monthly]
Recruiting PHASE2_PHASE3
-
Oct 2018 — Jan 2019 [monthly]
Recruiting PHASE2_PHASE3
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE2_PHASE3
-
Dec 2017 — Jun 2018 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2017 — Dec 2017 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Oct 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
For direct contact, visit the study record on ClinicalTrials.gov .